461 related articles for article (PubMed ID: 33417511)
1. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
Pelster MS; Gruschkus SK; Bassett R; Gombos DS; Shephard M; Posada L; Glover MS; Simien R; Diab A; Hwu P; Carter BW; Patel SP
J Clin Oncol; 2021 Feb; 39(6):599-607. PubMed ID: 33125309
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
6. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
9. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.
Tong TML; Burgmans MC; Speetjens FM; van Erkel AR; van der Meer RW; van Rijswijk CSP; Jonker-Bos MA; Roozen CFM; Sporrel-Blokland M; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Kapiteijn E
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):350-359. PubMed ID: 36624292
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
[TBL] [Abstract][Full Text] [Related]
11. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
Andresen NK; Røssevold AH; Quaghebeur C; Gilje B; Boge B; Gombos A; Falk RS; Mathiesen RR; Julsrud L; Garred Ø; Russnes HG; Lereim RR; Chauhan SK; Lingjærde OC; Dunn C; Naume B; Kyte JA
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242720
[TBL] [Abstract][Full Text] [Related]
13. Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma.
Hogg D; Monzon JG; Ernst S; Song X; McWhirter E; Savage KJ; Skinn B; Romeyer F; Smylie M
Curr Oncol; 2020 Aug; 27(4):204-214. PubMed ID: 32905202
[TBL] [Abstract][Full Text] [Related]
14. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
15. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
[TBL] [Abstract][Full Text] [Related]
16. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
[No Abstract] [Full Text] [Related]
17. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Postow MA; Goldman DA; Shoushtari AN; Betof Warner A; Callahan MK; Momtaz P; Smithy JW; Naito E; Cugliari MK; Raber V; Eton O; Nair SG; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2022 Apr; 40(10):1059-1067. PubMed ID: 34928709
[TBL] [Abstract][Full Text] [Related]
18. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
[TBL] [Abstract][Full Text] [Related]
20. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
